Results 121 to 130 of about 3,056 (181)

A Severe Symptomatic Case of Amyloid-Related Imaging Abnormalities After Donanemab Infusion. [PDF]

Cureus
Harikumar N, Gupta M, Al Janabi T, Mand KK.   +3 more
europepmc   +1 more source

Real-world determinants of time to initiation of anti-amyloid treatments: comparative data from private and academic practice settings. [PDF]

Alzheimers Dement (Amst)
Mehta V, Singh D, Kelman J, Nimma S, Lutz H, Schnee A, Weisman D, Rosenbloom MH.   +7 more
europepmc   +1 more source

Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia. [PDF]

Med J Aust
Gao L, Watson R, Yassi N.
europepmc   +1 more source

Response to “Variability of cognitive changes after donanemab treatment”

Alzheimer's & Dementia
Daly, Timothy, Kepp, Kasper P, Imbimbo, Bruno P   +2 more
openaire   +3 more sources

Therapeutic Landscape of Early Symptomatic Alzheimer's Disease Translated into Everyday Practice for Geriatric Providers. [PDF]

Clin Interv Aging
Bailey-Taylor MJ, Morrow P, Hendrix J, Galluzzi KE, Sharafsaleh G.   +4 more
europepmc   +1 more source

What should convince a clinician of disease modification in Alzheimer's disease clinical trials? [PDF]

Alzheimers Dement
Hazan J, Liu KY, Howard R.
europepmc   +1 more source

Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer's Disease: An Indirect, Comparative Interpretation of Phase 3 Trials. [PDF]

Dement Neurocogn Disord
Shim Y.
europepmc   +1 more source

Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions. [PDF]

Front Neurol
Zupan M, Prelog PR, Kramberger MG, Frol S.   +3 more
europepmc   +1 more source

The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Dinnerstein E.
europepmc   +1 more source

Letter to the Editor "Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J-ADNI Study". [PDF]

Geriatr Gerontol Int
Pradhan S.
europepmc   +1 more source